PBAC Call for Comments

Do you suffer from Atopic Dermatitis?

If so, you may want to comment on the Pfizer PBAC Submission for Staquis® (Crisaborole) https://www.healthdirect.gov.au/medicines/brand/amt,1397911000168107/staquis which is an ointment used on the skin (topical) to treat mild to moderate eczema (atopic dermatitis) in adults and children 2 years of age and older.

The Agenda for the November 2020 PBAC meeting is now available. Your comments are welcome whether you are a patient, carer, member of the public, health professional or member of a consumer interest group. The company applying for subsidy under the Pharmaceutical Benefits Scheme has already provided the PBAC with detailed clinical and economic data in support of the application. You are welcome to provide comments, for consideration by the PBAC, from a personal or group perspective on the impact of the condition addressed in the application.

To provide your input for the submission, please go to the PBAC online submission form on the PBAC website https://www1.health.gov.au/internet/main/publishing.nsf/Content/PBAC_online_submission_form

When you have completed the form and pressed the SUBMIT button, your form will be sent electronically to the PBAC Secretariat and you will receive email confirmation of receipt which will include a copy of your comments.

Hurry, your opportunity to comment closes on 7 October 2020, so make sure you get in before then!

Spring Skin Tips